SCHEMBL92571

SCHEMBL92571

Cc1cc(Cl)c(NC(=O)c2c[nH]c3ccccc23)cc1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.57
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
STING1 Q86WV6 2/20 0.50
CFTR P13569 7/20 0.49
NHERF1 O14745 1/20 0.49
MAOB P27338 1/20 0.48
NR4A2 P43354 1/20 0.45
CREBBP Q92793 1/20 0.45
PBRM1 Q86U86 1/20 0.45
IGF1R P08069 1/20 0.45
SRC P12931 1/20 0.45
ADORA3 P0DMS8 1/20 0.44
ADRB3 P13945 1/20 0.44
TBXA2R P21731 1/20 0.44
SLC6A2 P23975 1/20 0.44
AGTR1 P30556 1/20 0.44
MC4R P32245 1/20 0.44
PTGS2 P35354 1/20 0.44
SLC6A3 Q01959 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL92374 0.89 NPC1 (0.61) NPC1MEN1KMT2ASTING1CFTR
SCHEMBL92574 0.89 NPC1 (0.61) NPC1MEN1KMT2ASTING1CFTR
SCHEMBL92367 0.87 NHERF1 (0.46) NPC1MEN1KMT2ASTING1CFTR
SCHEMBL92389 0.87 NPC1 (0.42) NPC1MEN1KMT2ANHERF1NR4A2
SCHEMBL92355 0.84 KMT2A (0.67) NPC1MEN1KMT2ASTING1CFTR
SCHEMBL73753 0.82 NHERF1 (0.51) NPC1MEN1KMT2ACFTRNHERF1
SCHEMBL92581 0.82 RAB9A (0.64) NPC1MEN1KMT2ASTING1CFTR
SCHEMBL72295 0.82 PKM (0.54) NPC1MEN1KMT2ACFTRNHERF1
SCHEMBL24170257 0.80 KCNMA1 (0.57) NPC1MEN1KMT2ARAB9A
SCHEMBL92242 0.80 RAB9A (0.64) NPC1MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 NPC1 680/4885MEN1 4254/4885KMT2A 568/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 NPC1 551/4885MEN1 4337/4885KMT2A 656/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 NPC1 624/4885MEN1 4226/4885KMT2A 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.